Vzaimodeistviem okislennogo periodatom vodorastvorimogo galaktomannana s doksorubitsinom ili N-(L-lizil)doksorubitsinom polucheny sootvetstvuyushchie novye vodorastvorimye kon"yugaty v vide osnovanii Shiffa (DGM-1 i DGM-2). Vodorastvorimyi galaktomannan (DAVANAT, kommercheskii produkt firmy “Pro-Pharmaceuticals”) poluchen iz vysokomolekulyarnogo galaktomannana semyan rasteniya Cyamopsis tetragonoloba (guarovaya kamed') putem chastichnogo kislotnogo gidroliza. Izuchena ustoichivost' kon"yugatov v vodnykh rastvorakh. Antiproliferativnaya aktivnost' DGM-1 na modelyakh – kletochnykh liniyakh myshinoi melanomy B16-F1, raka grudi cheloveka MCF-7 (HTB-22) i raka tolstoi kishki cheloveka HT-29 (HTB-38) sopostavima s takovoi dlya doksorubitsina. DGM-2 maloaktiven vo vsekh trekh testakh. Na osnovanii poluchennykh dannykh DGM-1 mozhno rassmatrivat' kak vysokomolekulyarnuyu depo-formu doksorubitsina.

Spisok literatury

1. Garin A.M., Khlebnov A.V. Spravochnik prakticheskoi khimioterapii opukholei. M.: Asta Medika AG, 1995.
2. Arcamone F. Doxorubicin anticancer antibiotics. London, New-York;
   San Francisco: Acad. Press, 1981.
3. Pratesi G., Monestiroli S.V. // Curr. Med. Chem. 2001. V. 8. P. 9–13.
4. Perevodchikova N.I., Preobrazhenskaya M.N. // Novye tsitostatiki v lechenii zlokachestvennykh opukholei / Red. Gorbunova V.A. M., 1998. C. 61–74.
5. Monneret C. // Eur. J. of Med. Chem. 2001. V. 36. P. 483–493.
6. Olsuf'eva E.N. // Bioorgan. khimiya. 1990. T. 16. C. 1445–1463.
7. Olsuf'eva E.N. // Bioorgan. khimiya. 1992. T. 18. C. 149–180.
8. Damen E., De Groot F., Scheeren H. // Expert Opinion on Therapeutic Patents. 2001. V. 11. P. 651–666.
9. De Groot F., Damen E., Scheeren H. // Curr. Med. Chem. 2001. V. 8. P. 1093–1122.
10. Seymour L. // Crit. Rev. Ther. Drug Carrier Syst. 1992. V. 9. P. 135–187.
11. Rihova B., Etrych T., Pechar M., Jelinkova M., Stastny M., Hovorka O., Kovar M., Ulbrich K. // J. Control Release. 2001. V. 74. P. 225–232.
12. Kopeckova D., Minko T., Rubinstein A., Kopecek J. // Eur. J. Cancer. 2004. V. 40. P. 148–157.
13. Jelinkova M., Storhaln J., Etrych T., Ulrich K., Rihova B. // Pharm. Res. 2003. V. 20. P. 1558–1564.
14. Langer M., Kratz F., Rothen-Rutishauser B., Wunderli-Allenspach H., Beck-Sickinger A. // J. Med. Chem. 2001. V. 44. P. 1341–1348.
15. Lutsenko S., Feldman N., Severin S. // J. Drug Target. 2002. V. 10. P. 567–571.
16. Kratz F., Beyer U., Collery P., Lechenault F., Cazabat A., Schumacher P., Falken U., Unger C. // Biol. Pharm. Bull. 1998. V. 21. P. 56–61.
17. Domb A.J., Benita S., Polacheck I., Linden G. Patent US 6011008. 2000. CA 2000. V. 132. P. 69331.
18. Vogel C.-W. Immunoconjugates. Antibody conjugates in radioimaging and therapy of cancer. Oxford: Oxford University Press, 1987. P. 189–217.
19. Aboud-Pirak E., Hurwitz E., Bellot F., Schlessinger J., Sela M. // Proc. Natl. Acad. Sci. USA. 1989. V. 86. P. 3778–3781.
20. Hurwitz E., Maron R., Arnon R., Wilcher M., Sela M. // Eur. J. Cancer. 1978. V. 14. P. 1213–1220.
21. Ahmad S., Tester R. //22^nd Intern. Carbohydrate Symp. Abstr. 23–27 July 2004. Glasgow, UK, C37.
22. Olsufyeva E.N., Tevyashova A.N., Trestchalin I.D., Preobrazhenskaya M.N., Platt D., Klyosov A. // Carbohydrate Res. 2003. V. 338. P. 1359–1367.
23. El Khadem H.S. Anthracycline antibiotics. New York: Acad. Press, 1982. P. 124–138.
24. Silverman R. Organic chemistry of drug design and drug action: San Diego: Elsevier Acad. Press, 2004.
25. Vasta G.R., Ahmed H., Odom E.W. // Curr. Opinion in Struct. Biology. 2004. V. 14. P. 616–630.
26. Debray C., Vereecken P., Belot N., Tiellard P., Brion J.-P., Pandolfo M., Pochet R. // Biochem. and Biophys. Res. Communs. 2004. V. 325. P. 1393–1398.
27. Cairo C.W., Gestwicki J.E., Kanai M., Kiessling L.L. // JACS. 2002. V. 124. P. 1615–1619.
28. Klyosov A.A., Platt D., Zomer E. // Preclinica. 2003. V. 1. P. 175–186.
29. Levin Y., Sela B. // Curr. Chemotherapy and Infections. 1980. V. 25. P. 1685–1687.
30. AnaSpec, Inc., San Jose, CA 95131, cast number 22501.